Anti-angiogenic Therapy Versus Dose-Dense Paclitaxel Therapy for Frontline Treatment of Epithelial Ovarian Cancer: Review of Phase III Randomized Clinical Trials
Crossref DOI link: https://doi.org/10.1007/s11912-014-0412-2
Published Online: 2014-10-08
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Slaughter, Katrina N.
Moore, Kathleen N.
Mannel, Robert S.
Text and Data Mining valid from 2014-10-08